Drug_name,Brand_name,Sponsor,Properties,Review_type,Year,Indication,Indication_EFO,DiseaseId,TA,Drug_name_original,DrugId,Why_has_no
DAPAGLIFLOZIN,Farxiga,AstraZeneca,SGLT2 inhibitor,S,2014,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,Metabolic,Dapagliflozin,CHEMBL429910,Related indication (Glycosuria)
TASIMELTEON,Hetlioz,Vanda,Melatonin-receptor agonist,"P, O",2014,Non-24-hour sleep-wake disorder,sleep-wake disorder,MONDO_0003406,Neurological,Tasimelteon,CHEMBL2103822,Related indication (chronotype measurement)
ELOSULFASE ALFA,Vimizim,BioMarin,Hydrolytic lysosomal glycosaminoglycan-specific enzyme,"P, O",2014,Mucopolysaccharidosis type IVA,mucopolysaccharidosis type 4A,MONDO_0009659,Metabolic,Elosulfase alfa,CHEMBL2108676,
DROXIDOPA,Northera,Lundbeck,Synthetic amino-acid precursor of noradrenaline; MOA unknown,"P, O, A",2014,Light-headedness in patients with neurogenic orthostatic hypotension,primary orthostatic hypotension,MONDO_0015914,Neurological,Droxidopa,CHEMBL2103827,
METRELEPTIN,Myalept,Amylin,Leptin analogue,"P, O",2014,Leptin deficiency in patients with congenital or acquired generalized lipodystrophy,congenital generalized lipodystrophy,EFO_1000681,Endocrine,Metreleptin,CHEMBL2107857,
FLORBETABEN-F18,Neuraceq,Piramal Imaging,Radioactive diagnostic agent,S,2014,Imaging of the brain to estimate density of neuritic amyloid-beta plaques,neuritic plaque measurement,EFO_0006798,Imaging,Florbetaben-F18,CHEMBL566752,
MILTEFOSINE,Impavido,Knight,MOA unknown,"P, O",2014,Leishmaniasis,Leishmaniasis,EFO_0005044,Infectious,Miltefosine,CHEMBL125,
APREMILAST,Otezla,Celgene,Phosphodiesterase 4 inhibitor,S,2014,Psoriatic arthritis and plaque psoriasis,psoriatic arthritis; psoriasis vulgaris,EFO_0003778; EFO_1001494,Dermatology,Apremilast,CHEMBL514800,
ALBIGLUTIDE,Tanzeum,GlaxoSmithKline,GLP1-receptor agonist,S,2014,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,Metabolic,Albiglutide,CHEMBL2107841,
RAMUCIRUMAB,Cyramza,Eli Lilly,VEGFR2 antagonist,"P, O",2014,Gastric cancer,gastric cancer,MONDO_0001056,Oncology,Ramucirumab,CHEMBL1743062,
SILTUXIMAB,Sylvant,Janssen Biotech,IL-6-specific antibody,"P, O",2014,Multicentric Castleman's disease,Castleman disease,MONDO_0015564,Other,Siltuximab,CHEMBL1743070,
CERITINIB,Zykadia,Novartis,"Kinase inhibitor against ALK, IGF1R, insulin receptor and ROS1","P, O, B, A",2014,ALK-positive metastatic NSCLC,non-small cell lung carcinoma,EFO_0003060,Oncology,Ceritinib,CHEMBL2403108,
VORAPAXAR,Zontivity,Merck & Co.,Protease-activated receptor 1 antagonist,S,2014,Thrombotic cardiovascular events (after myocardial infarction or with peripheral arterial disease*),myocardial infarction; peripheral arterial disease,EFO_0000612; EFO_0004265,Cardiovascular,Vorapaxar,CHEMBL493982,Related indication (mean corpuscular volume)
VEDOLIZUMAB,Entyvio,Takeda,Integrin-receptor antagonist,P,2014,Ulcerative colitis and Crohn's disease,ulcerative colitis; Crohn's disease,EFO_0000729; EFO_0000384,Gastrointestinal,Vedolizumab,CHEMBL1743087,
DALBAVANCIN,Dalvance,Durata,Semisynthetic lipoglycopeptide,P,2014,ABSSSI (Acute Bacterial Skin and Skin Structure Infections),staphylococcal skin infections,EFO_1001849,Infectious,Dalbavancin,CHEMBL3301669,
EFINACONAZOLE,Jublia,Dow,Azole antifungal,S,2014,Onychomycosis of the toenails,paronychia,EFO_0007421,Dermatology,Efinaconazole,CHEMBL2103877,
TEDIZOLID,Sivextro,Cubist,Oxazolidinone-class antibacterial,P,2014,ABSSSI (Acute Bacterial Skin and Skin Structure Infections),staphylococcal skin infections,EFO_1001849,Infectious,Tedizolid,CHEMBL1257051,
BELINOSTAT,Beleodaq,Spectrum,Histone-deacetylase inhibitor,"P, O, A",2014,Peripheral T-cell lymphoma,unspecified peripheral T-cell lymphoma,EFO_0000211,Hematology,Belinostat,CHEMBL408513,
TAVABOROLE,Kerydin,Anacor,Oxaborole antifungal,S,2014,Onychomycosis of the toenails,paronychia,EFO_0007421,Dermatology,Tavaborole,CHEMBL443052,
IDELALISIB,Zydelig,Gilead Sciences,PI3Kâp110-delta subunit inhibitor,"P, O, B, A",2014,"CLL, B-cell non-Hodgkin lymphoma and SLL",chronic lymphocytic leukemia; B-cell non-Hodgkins lymphoma,EFO_0000095; EFO_1001938,Hematology,Idelalisib,CHEMBL2216870,
OLODATEROL,Striverdi Respimat,Boehringer Ingelheim,Long-acting beta2-adrenoceptor agonist,S,2014,COPD,chronic obstructive pulmonary disease,EFO_0000341,Respiratory,Olodaterol,CHEMBL605846,
EMPAGLIFLOZIN,Jardiance,Boehringer Ingelheim,SGLT2 inhibitor,S,2014,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,Metabolic,Empagliflozin,CHEMBL2107830,Related indication (Glycosuria)
ORITAVANCIN,Orbactiv,The Medicines Company,Semi-synthetic lipoglycopeptide,P,2014,ABSSSI (Acute Bacterial Skin and Skin Structure Infections),staphylococcal skin infections,EFO_1001849,Infectious,Oritavancin,CHEMBL1688530,
SUVOREXANT,Belsomra,Merck & Co.,Orexin-receptor antagonist,S,2014,Insomnia,insomnia,EFO_0004698,Mental health,Suvorexant,CHEMBL1083659,
PEGINTERFERON BETA-1A,Plegridy,Biogen Idec,Long-acting interferon-beta1A,S,2014,Relapsing multiple sclerosis,relapsing-remitting multiple sclerosis,EFO_0003929,Neurological,Peginterferon beta-1A,CHEMBL2108677,Related indication (cytokine measurement)
ELIGLUSTAT,Cerdelga,Genzyme,Glucosylceramide-synthase inhibitor,"P, O",2014,Gaucher's disease,Gaucher disease,MONDO_0018150,Metabolic,Eliglustat,CHEMBL2110588,Related target (SMPD1)
PEMBROLIZUMAB,Keytruda,Merck & Co.,PD1-specific antibody,"P, O, B, A",2014,Metastatic melanoma *and others (2021 approval),metastatic melanoma; cancer,EFO_0002617; MONDO_0004992,Oncology,Pembrolizumab,CHEMBL3137343,"Downstream regulator (CD274), Post-approval"
NALOXEGOL,Movantik,AstraZeneca,Opioid-receptor antagonist,S,2014,Opioid-induced constipation,Constipation,HP_0002019,Gastrointestinal,Naloxegol,CHEMBL2219418,Cohort problem
DULAGLUTIDE,Trulicity,Eli Lilly,GLP1-receptor agonist,S,2014,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,Metabolic,Dulaglutide,CHEMBL2108027,
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES,Lumason,Bracco,Ultrasound contrast agent,S,2014,Cardiovascular imaging,NA,NA,Imaging,Sulfur hexafluoride lipid-type A microspheres,NA,
NETUPITANT,Akynzeo,Helsinn,An NK1-receptor antagonist plus a 5-HT3-receptor antagonist,S,2014,Chemotherapy-related nausea,Chemotherapy-induced nausea and vomiting,EFO_0006911,Other,Netupitant; palonosetron,CHEMBL206253,Cohort problem
PALONOSETRON,Akynzeo,Helsinn,An NK1-receptor antagonist plus a 5-HT3-receptor antagonist,S,2014,Chemotherapy-related nausea,Chemotherapy-induced nausea and vomiting,EFO_0006911,Other,Netupitant; palonosetron,CHEMBL1189679,Cohort problem
LEDIPASVIR,Harvoni,Gilead Sciences,An NS5A inhibitor plus an HCV nucleotide-analogue NS5B-polymerase inhibitor,"P, B",2014,Genotype 1 HCV,hepatitis C virus infection,EFO_0003047,Infectious,Ledipasvir; sofosbuvir,CHEMBL2374220,
SOFOSBUVIR,Harvoni,Gilead Sciences,An NS5A inhibitor plus an HCV nucleotide-analogue NS5B-polymerase inhibitor,"P, B",2014,Genotype 1 HCV,hepatitis C virus infection,EFO_0003047,Infectious,Ledipasvir; sofosbuvir,CHEMBL1259059,
PIRFENIDONE,Esbriet,InterMune,MOA unknown,"P, O, B",2014,IPF (idiopathic pulmonary fibrosis),idiopathic pulmonary fibrosis,EFO_0000768,Respiratory,Pirfenidone,CHEMBL1256391,
NINTEDANIB,Ofev,Boehringer Ingelheim,"Kinase inhibitor against PDGFRs, FGFRs, VEGFRs and FLT3","P, O, B",2014,IPF (idiopathic pulmonary fibrosis),idiopathic pulmonary fibrosis,EFO_0000768,Respiratory,Nintedanib,CHEMBL502835,
BLINATUMOMAB,Blincyto,Amgen,CD19- and CD3-bispecific antibody,"P, O, B, A",2014,B-ALL,precursor B-cell acute lymphoblastic leukemia,MONDO_0020511,Oncology,Blinatumomab,CHEMBL1742992,Unknown (cancer immunotherapy)
FINAFLOXACIN,Xtoro,Alcon,Fluoroquinolone antimicrobial,P,2014,Acute otitis externa (swimmer's ear),otitis externa,EFO_0009560,Otolaryngology,Finafloxacin,CHEMBL1908370,
OLAPARIB,Lynparza,AstraZeneca,PARP inhibitor,"P, O, A",2014,Advanced BRCA-mutated ovarian cancer,ovarian cancer,MONDO_0008170,Oncology,Olaparib,CHEMBL521686,
OMBITASVIR,Viekira Pak,AbbVie,An NS5A inhibitor plus an NS3A- and NS4A-protease inhibitor plus a non-nucleoside NS5B-palm-polymerase inhibitor plus a CYP3A inhibitor,"P, B",2014,Chronic HCV genotype 1 infection,hepatitis C virus infection,EFO_0003047,Infectious,Ombitasvir; paritaprevir; dasabuvir; ritonavir,CHEMBL3127326,
PARITAPREVIR,Viekira Pak,AbbVie,An NS5A inhibitor plus an NS3A- and NS4A-protease inhibitor plus a non-nucleoside NS5B-palm-polymerase inhibitor plus a CYP3A inhibitor,"P, B",2014,Chronic HCV genotype 1 infection,hepatitis C virus infection,EFO_0003047,Infectious,Ombitasvir; paritaprevir; dasabuvir; ritonavir,CHEMBL3391662,
DASABUVIR,Viekira Pak,AbbVie,An NS5A inhibitor plus an NS3A- and NS4A-protease inhibitor plus a non-nucleoside NS5B-palm-polymerase inhibitor plus a CYP3A inhibitor,"P, B",2014,Chronic HCV genotype 1 infection,hepatitis C virus infection,EFO_0003047,Infectious,Ombitasvir; paritaprevir; dasabuvir; ritonavir,CHEMBL3137312,
RITONAVIR,Viekira Pak,AbbVie,An NS5A inhibitor plus an NS3A- and NS4A-protease inhibitor plus a non-nucleoside NS5B-palm-polymerase inhibitor plus a CYP3A inhibitor,"P, B",2014,Chronic HCV genotype 1 infection,hepatitis C virus infection,EFO_0003047,Infectious,Ombitasvir; paritaprevir; dasabuvir; ritonavir,CHEMBL163,
CEFTOLOZANE,Zerbaxa,Cubist,A cephalosporin antibacterial plus a beta-lactamase inhibitor,P,2014,Complicated intra-abdominal infections and complicated urinary tract infections,infection,EFO_0000544,Infectious,Ceftolozane; tazobactam,CHEMBL2103872,
TAZOBACTAM,Zerbaxa,Cubist,A cephalosporin antibacterial plus a beta-lactamase inhibitor,P,2014,Complicated intra-abdominal infections and complicated urinary tract infections,infection,EFO_0000544,Infectious,Ceftolozane; tazobactam,CHEMBL404,
PERAMIVIR,Rapivab,BioCryst,Neuraminidase inhibitor,S,2014,Influenza infection,influenza,EFO_0007328,Infectious,Peramivir,CHEMBL3989402,
PERAMIVIR,Rapivab,BioCryst,Neuraminidase inhibitor,S,2014,Influenza infection,influenza,EFO_0007328,Infectious,Peramivir,CHEMBL139367,
NIVOLUMAB,Opdivo,Bristol-Myers Squibb,PD1 inhibitor,"P, O, B, A",2014,Unresectable or metastatic melanoma,metastatic melanoma; cancer,EFO_0002617; MONDO_0004992,Oncology,Nivolumab,CHEMBL2108738,"Downstream regulator (CD274), Post-approval"
EDOXABAN,Savaysa,Daiichi Sankyo,Factor Xa inhibitor,S,2015,"Risk of stroke and systemic embolism in NVAF, and deep vein thrombosis",atrial fibrillation; deep vein thrombosis,EFO_0000275; EFO_0003907,Cardiovascular,Edoxaban,CHEMBL1269025,
SECUKINUMAB,Cosentyx,Novartis,IL-17A antagonist,S,2015,"Plaque psoriasis, *psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.",psoriasis vulgaris,EFO_1001494,Dermatology,Secukinumab,CHEMBL1743068,
PARATHYROID HORMONE,Natpara,NPS Pharma,Hormonal injection,"S, O",2015,Hypocalcaemia in patients with hypoparathyroidism,hypoparathyroidism; Hypocalcemia,EFO_0009451; HP_0002901,Endocrine,Parathyroid hormone,CHEMBL2108078,
PALBOCICLIB,Ibrance,Pfizer,CDK4 and CDK6 inhibitor,"P, B, A",2015,"ER-positive, HER2-negative advanced breast cancer",HER2 negative breast carcinoma,EFO_0009780,Oncology,Palbociclib,CHEMBL189963,Related indication (arthritis)
LENVATINIB,Lenvima,Eisai,VEGFR inhibitor,"P, O",2015,Thyroid cancer,thyroid cancer,MONDO_0002108,Oncology,Lenvatinib,CHEMBL1289601,
PANOBINOSTAT,Farydak,Novartis,Histone deacetylase inhibitor,"P, O, A",2015,Multiple myeloma,multiple myeloma,EFO_0001378,Oncology,Panobinostat,CHEMBL483254,
AVIBACTAM,Avycaz,Allergan,A beta-lactamase inhibitor and a cephalosporin,P,2015,Complicated intra-abdominal infections and complicated urinary tract infections,infection,EFO_0000544,Infectious,Avibactam; ceftazidime,CHEMBL1689063,
CEFTAZIDIME,Avycaz,Allergan,A beta-lactamase inhibitor and a cephalosporin,P,2015,Complicated intra-abdominal infections and complicated urinary tract infections,infection,EFO_0000544,Infectious,Avibactam; ceftazidime,CHEMBL44354,
ISAVUCONAZONIUM,Cresemba,Astellas,Azole antifungal,"P, O",2015,Antifungal,aspergillosis; mucormycosis,EFO_0007157; EFO_0007380,Infectious,Isavuconazonium,CHEMBL1183349,
DINUTUXIMAB,Unituxin,United Therapeutics,GD2-binding mAb,"P, O",2015,Neuroblastoma,neuroblastoma,EFO_0000621,Oncology,Dinutuximab,CHEMBL3137342,
CHOLIC ACID,Cholbam,Retrophin,A primary bile acid,"P, O",2015,Bile acid synthesis disorders and peroxisomal disorders,peroxisomal disease; Disorder of bile acid synthesis,MONDO_0019053; Orphanet_79168,Metabolic,Cholic acid,CHEMBL205596,Target (NR1H4)
IVABRADINE,Corlanor,Amgen,Hyperpolarization-activated cyclic nucleotide-gated channel blocker,P,2015,Chronic heart failure,congestive heart failure,EFO_0000373,Cardiovascular,Ivabradine,CHEMBL471737,
DEOXYCHOLIC ACID,Kybella,Kythera,Cytolytic drug,S,2015,Fat below the chin,body fat distribution,EFO_0004341,Other,Deoxycholic acid,CHEMBL406393,Downstream?
ELUXADOLINE,Viberzi,Allergan,Mu-opioid receptor agonist,P,2015,Irritable bowel syndrome,irritable bowel syndrome,EFO_0000555,Gastrointestinal,Eluxadoline,CHEMBL2159122,Unknown
CANGRELOR,Kengreal,Medicines Company,P2Y12 platelet inhibitor,S,2015,"Myocardial infarction, repeat coronary revascularization, and stent thrombosis",myocardial infarction,EFO_0000612,Cardiovascular,Cangrelor,CHEMBL334966,Related indication (Abnormal bleeding)
IVACAFTOR,Orkambi,Vertex,CFTR potentiator plus CFTR corrector,"P, O, B",2015,Cystic fibrosis in patients with homozygous DF508 CFTR mutation,cystic fibrosis,MONDO_0009061,Other,Ivacaftor; lumacaftor,CHEMBL2010601,
LUMACAFTOR,Orkambi,Vertex,CFTR potentiator plus CFTR corrector,"P, O, B",2015,Cystic fibrosis in patients with homozygous DF508 CFTR mutation,cystic fibrosis,MONDO_0009061,Other,Ivacaftor; lumacaftor,CHEMBL2103870,
SACUBITRIL,Entresto,Novartis,A neprilysin inhibitor plus an angiotensin II receptor blocker,P,2015,Chronic heart failure,congestive heart failure,EFO_0000373,Cardiovascular,Sacubitril; valsartan,CHEMBL3137301,
VALSARTAN,Entresto,Novartis,A neprilysin inhibitor plus an angiotensin II receptor blocker,P,2015,Chronic heart failure,congestive heart failure,EFO_0000373,Cardiovascular,Sacubitril; valsartan,CHEMBL1069,
BREXPIPRAZOLE,Rexulti,Otsuka,Atypical antipsychotic,S,2015,MDD and schizophrenia,major depressive disorder; schizophrenia,MONDO_0002009; MONDO_0005090,Mental health,Brexpiprazole,CHEMBL2105760,
ALIROCUMAB,Praluent,Sanofi,PCSK9 inhibitor,P,2015,LDL lowering,LDL cholesterol change measurement,EFO_0007804,Cardiovascular,Alirocumab,CHEMBL2109540,
SONIDEGIB,Odomzo,Novartis,Smoothened inhibitor,S,2015,Basal cell carcinoma,basal cell carcinoma,EFO_0004193,Oncology,Sonidegib,CHEMBL2105737,
DACLATASVIR,Daklinza,Bristol-Myers Squibb,NS5A inhibitor,P,2015,HCV,hepatitis C virus infection,EFO_0003047,Infectious,Daclatasvir,CHEMBL2023898,
FLIBANSERIN,Addyi,Sprout,Serotonin receptor modulator,S,2015,Hypoactive sexual desire disorder,sexual dysfunction,EFO_0004714,Other,Flibanserin,CHEMBL231068,Related indication (female reproductive system disease)
EVOLOCUMAB,Repatha,Amgen,PCSK9 inhibitor,"S, O",2015,LDL lowering,LDL cholesterol change measurement,EFO_0007804,Cardiovascular,Evolocumab,CHEMBL2364655,
ROLAPITANT,Varubi,Tesaro,Neurokinin 1 receptor antagonist,S,2015,Nausea and vomiting associated with chemotherapy,Chemotherapy-induced nausea and vomiting,EFO_0006911,Other,Rolapitant,CHEMBL3707331,Cohort problem
URIDINE,Xuriden,Wellstat,Pyrimidine analogue,"P, O, B",2015,Hereditary orotic aciduria,Hereditary orotic aciduria,Orphanet_30,Metabolic,Uridine,CHEMBL100259,
CARIPRAZINE,Vraylar,Forest,Atypical antipsychotic,S,2015,Schizophrenia and bipolar 1 disorder,Schizophrenia; bipolar disorder,MONDO_0005090; MONDO_0004985,Mental health,Cariprazine,CHEMBL2028019,
TIPIRACIL,Lonsurf,Taiho,Thymidine phosphorylase inhibitor plus a nucleoside metabolic inhibitor,S,2015,Colorectal cancer,colorectal cancer,EFO_0005842,Oncology,Tipiracil; trifluridine,CHEMBL235668,
TRIFLURIDINE,Lonsurf,Taiho,Thymidine phosphorylase inhibitor plus a nucleoside metabolic inhibitor,S,2015,Colorectal cancer,colorectal cancer,EFO_0005842,Oncology,Tipiracil; trifluridine,CHEMBL1129,
INSULIN DEGLUDEC,Tresiba,Novo Nordisk,Long-acting insulin,S,2015,Diabetes,diabetes mellitus,EFO_0000400,Metabolic,Insulin degludec,CHEMBL2107869,
ARIPIPRAZOLE LAUROXIL,Aristada,Alkermes,Extended release atypical antipsychotic,S,2015,Schizophrenia,schizophrenia,MONDO_0005090,Mental health,Aripiprazole lauroxil,CHEMBL2219425,
IDARUCIZUMAB,Praxbind,Boehringer Ingelheim,Dabigatran-binding mAb fragment,"P, O, B, A",2015,Reversal of anticoagulant effects of dabigatran,response to anticoagulant,GO_0061476,Other,Idarucizumab,CHEMBL3544996,
PATIROMER SORBITEX,Veltassa,Relypsa,Potassium binder,S,2015,Hyperkalaemia,Hyperkalemia,HP_0002153,Other,Patiromer sorbitex,CHEMBL2107840,
ASFOTASE ALFA,Strensiq,Alexion,Alkaline phosphatase,"P, O, B",2015,Hypophosphatasia,hypophosphatasia,MONDO_0018570,Other,Asfotase alfa,CHEMBL2108311,
TRABECTEDIN,Yondelis,Johnson & Johnson,Alkylating drug,"P, O",2015,Liposarcoma or leiomyosarcoma,liposarcoma; leiomyosarcoma,EFO_0000569; EFO_0000564,Oncology,Trabectedin,CHEMBL450449,
MEPOLIZUMAB,Nucala,GlaxoSmithKline,IL-5 antagonist,S,2015,Severe asthma,Status Asthmaticus,EFO_0008590,Respiratory,Mepolizumab,CHEMBL2108429,
ELVITEGRAVIR,Genvoya,Gilead,An INSTI plus a CYP3A inhibitor plus two nucleoside analogue reverse transcriptase inhibitors,S,2015,HIV,HIV infection,EFO_0000764,Infectious,Elvitegravir; cobicistat; emtricitabine; tenofovir,CHEMBL204656,
COBICISTAT,Genvoya,Gilead,An INSTI plus a CYP3A inhibitor plus two nucleoside analogue reverse transcriptase inhibitors,S,2015,HIV,HIV infection,EFO_0000764,Infectious,Elvitegravir; cobicistat; emtricitabine; tenofovir,CHEMBL2095208,
EMTRICITABINE,Genvoya,Gilead,An INSTI plus a CYP3A inhibitor plus two nucleoside analogue reverse transcriptase inhibitors,S,2015,HIV,HIV infection,EFO_0000764,Infectious,Elvitegravir; cobicistat; emtricitabine; tenofovir,CHEMBL885,
TENOFOVIR,Genvoya,Gilead,An INSTI plus a CYP3A inhibitor plus two nucleoside analogue reverse transcriptase inhibitors,S,2015,HIV,HIV infection,EFO_0000764,Infectious,Elvitegravir; cobicistat; emtricitabine; tenofovir,CHEMBL483,
COBIMETINIB,Cotellic,Genentech,MEK inhibitor,"P, O",2015,Melanoma with BRAFV600E/K mutations,melanoma,EFO_0000756,Oncology,Cobimetinib,CHEMBL2146883,
OSIMERTINIB,Tagrisso,AstraZeneca,EGFR inhibitor,"P, O, B, A",2015,NSCLC with EGFRT790M mutations,non-small cell lung carcinoma,EFO_0003060,Oncology,Osimertinib,CHEMBL3353410,
DARATUMUMAB,Darzalex,Johnson & Johnson,CD38-directed mAb,"P, O, B, A",2015,Multiple myeloma,multiple myeloma,EFO_0001378,Oncology,Daratumumab,CHEMBL1743007,
IXAZOMIB,Ninlaro,Takeda,Oral proteasome inhibitor,"P, O",2015,Multiple myeloma,multiple myeloma,EFO_0001378,Oncology,Ixazomib,CHEMBL2141296,
NECITUMUMAB,Portrazza,Eli Lilly,EGFR antagonist,"S, O",2015,NSCLC,non-small cell lung carcinoma,EFO_0003060,Oncology,Necitumumab,CHEMBL1743047,
ELOTUZUMAB,Empliciti,Bristol-Myers Squibb,SLAMF7-directed mAb,"P, O, B",2015,Multiple myeloma,multiple myeloma,EFO_0001378,Oncology,Elotuzumab,CHEMBL1743010,
SEBELIPASE ALFA,Kanuma,Alexion,Enzyme replacement therapy,"P, O, B",2015,LAL deficiency,lysosomal acid lipase deficiency,MONDO_0010204,Metabolic,Sebelipase alfa,CHEMBL3039537,
ALECTINIB,Alecensa,Roche,ALK inhibitor,"P, O, B, A",2015,NSCLC,non-small cell lung carcinoma,EFO_0003060,Oncology,Alectinib,CHEMBL1738797,
SUGAMMADEX,Bridion,Merck & Co.,A modified gamma cyclodextrin,P,2015,Reversal of neuromuscular blockade during surgery,neuromuscular disease,EFO_1001902,Other,Sugammadex,CHEMBL2111107,Cohort problem
SELEXIPAG,Uptravi,Actelion,Prostacyclin receptor agonist,"S, O",2015,Pulmonary arterial hypertension,pulmonary arterial hypertension,EFO_0001361,Cardiovascular,Selexipag,CHEMBL238804,Downstream regulator (prostacyclin synthase)
LESINURAD,Zurampic,AstraZeneca,URAT1 inhibitor,S,2015,Gout,gout,EFO_0004274,Other,Lesinurad,CHEMBL2105720,